CVRx Appoints John Landry as Chief Financial Officer

CVRx names experienced medtech finance executive John Landry as CFO, with a staged transition following the company’s Q3 2026 Form 10-Q filing.

Rhea-AI Summary

CVRx (CVRX) appointed John Landry as Chief Financial Officer, succeeding Jared Oasheim, with the transition tied to the filing of CVRx’s Form 10‑Q for the quarter ending September 30, 2026.

Landry will join CVRx on October 12, 2026 and become CFO after that quarterly filing, while Oasheim remains for a transition period under his previously disclosed agreement. Landry currently serves as CFO of Nyxoah SA and previously spent 12 years at Vapotherm, where he led its IPO and built finance, investor relations and public reporting functions. His earlier roles included finance leadership positions at Salient Surgical Technologies, Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand. Landry holds a B.S. in Accountancy from Bentley College, is a CPA (inactive), and serves on the board of Liberate Medical.

Positive

• Experienced medtech CFO appointed with more than two decades of industry financial leadership
• Prior IPO and capital-raising track record at Vapotherm and Nyxoah SA
• Structured transition with outgoing CFO Jared Oasheim remaining for a defined handover period

Negative

• CFO change introduces leadership transition risk in the finance function during ongoing commercial scaling

Key Figures

CFO start date: October 12, 2026 CFO transition timing: Day after the Form 10-Q filing

CFO start date

October 12, 2026

John Landry joins CVRx

CFO transition timing

Day after the Form 10-Q filing

Quarter ending September 30, 2026

Key Terms

neuromodulation, form 10-q, ipo, cpa

4 terms

neuromodulation medical

"focused on developing, manufacturing and commercializing innovative neuromodulation solutions"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

form 10-q regulatory

"assume the CFO role on the day after the Company files its Form 10-Q"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

ipo financial

"He led us through our IPO and helped build the financial foundation"

An initial public offering (IPO) is the process by which a private company sells its shares to the public for the first time, making its ownership available on the stock market. This allows the company to raise money from a wide range of investors to fund growth or other goals. For investors, an IPO offers a chance to buy into a company early in its public journey, potentially benefiting if the company grows in value.

View in glossary

cpa financial

"He holds a B.S. in Accountancy from Bentley College, is a CPA (inactive)"

A Certified Public Accountant (CPA) is a licensed accounting professional who has passed standardized exams and met experience requirements to audit financial statements, prepare tax filings, and provide financial advice. Investors care because CPAs help ensure a company’s financial reports are accurate and trustworthy—like an independent mechanic inspecting a car before purchase—reducing the risk that numbers are misleading or contain errors that could affect investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Landry Brings Two Decades of Medtech and Public Company Finance Experience

MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q for the quarter ending September 30, 2026.   Mr. Oasheim will remain with the Company for a transition period consistent with his previously disclosed transition agreement.

"John is exactly the kind of finance leader we need for this next chapter," said Kevin Hykes, President and CEO of CVRx. "Over the past two decades, he has played a key role in building and financing high growth medical device companies introducing novel therapies like Barostim. He is a hands-on operational leader who has significant commercial and capital markets experience, and who is well known within the investment community. John’s experience driving growth while managing expenses is particularly relevant as we scale Barostim and reach more heart failure patients.

"I want to thank Jared for the significant impact he has had at the company since 2015. He led us through our IPO and helped build the financial foundation we stand on today," Hykes added. "We're grateful for his contributions and wish him success in his next chapter."

Mr. Landry brings more than two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), where he raised several rounds of capital and drove operational efficiencies to fund the company's U.S. commercial expansion. Before that, he spent 12 years at Vapotherm, Inc. (formerly NYSE: VAPO), most recently as Senior Vice President and CFO, where he led the company's IPO and built its finance, investor relations and public company reporting functions from the ground up. Earlier in his career, Mr. Landry held finance leadership roles at Salient Surgical Technologies (acquired by Medtronic in 2011), Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand. He holds a B.S. in Accountancy from Bentley College, is a CPA (inactive) and serves on the board of Liberate Medical, Inc.

"Barostim is changing how physicians treat heart failure and the positive impact it is having on patients’ lives is what drew me to this role," said John Landry. "I've spent most of my career in the medical device industry helping to build the infrastructure and operating discipline needed as companies scale their commercial efforts. I’m excited to join the CVRx team and see a real opportunity to bring that same operating discipline to support the business as we execute our commercial growth strategy."

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will John Landry join CVRx and officially assume the CFO role?

John Landry will join CVRx on October 12, 2026. He will assume the CFO role on the day after the company files its Form 10‑Q for the quarter ending September 30, 2026.

What is Jared Oasheim’s role during the transition at CVRx?

Jared Oasheim will remain with CVRx for a transition period that is consistent with his previously disclosed transition agreement, supporting an orderly handover of CFO responsibilities.

What relevant experience does John Landry bring to the CVRx CFO position?

John Landry has over two decades of financial leadership in the medical device industry. He is currently CFO of Nyxoah SA, where he raised several rounds of capital and drove operational efficiencies, and previously served 12 years at Vapotherm, most recently as SVP and CFO, leading its IPO and building finance, investor relations and public reporting functions.

What is John Landry’s educational and professional background in finance?

John Landry holds a B.S. in Accountancy from Bentley College, is a CPA (inactive), and serves on the board of Liberate Medical. Earlier in his career he held finance leadership roles at Salient Surgical Technologies, Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand.